November 25, 2015
The winners of Prix Galien Italy awards were announced during the ceremony held at the Circolo della Stampa in Milan.
The award for Best Innovative Drug was shared by Bristol Myers Squibb (BMS) for Opdivo® (nivolumab) and Merck Sharp & Dome (MSD), for Keytruda® (pembrolizumab).
The Board also awarded special commendation for Holoclar®, produced by the Italian pharmaceutical company headquartered in Parma Chiesi Farmaceutici, due to the high value innovative application in the treatment with stem cells.
The second award, intended for Research (carried out in Italy in clinical and experimental pharmacology from young researchers, aged up to 35) was awarded ex aequo to:
- Dr. Edoardo Bonavita, Laboratorio di Immunologia e infiammazione, Istituto Clinico Humanitas Rozzano (Milano)
- Dr. Camilla Fusi, Unità di Farmacologia e Oncologia, Dipartimento di Scienze della Salute, Università degli Studi di Firenze
For further information please contact Ms. Maria Teresa MARIANI, mariateresa.mariani@springer.com.
